STOCK TITAN
  1. Home
  2. News
  3. ETNB

89Bio, Inc. - ETNB STOCK NEWS

Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.

Overview

89Bio, Inc. (symbol: ETNB) is a United States-based clinical-stage biopharmaceutical company committed to advancing innovative therapies for patients with liver and cardiometabolic diseases. Employing cutting-edge glycoPEGylation technology, the company is focused on enhancing the biological activity and prolonging the half-life of its therapeutic candidates through advanced drug engineering. With a robust pipeline centered on conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG), 89Bio is addressing significant unmet clinical needs with precision and scientific rigor.

Core Business and Product Pipeline

The company’s primary focus is on the development and eventual commercialization of pegozafermin, a specifically engineered fibroblast growth factor 21 (FGF21) analog. This molecule, enhanced by unique glycoPEGylated technology, has been designed to exert potent anti-fibrotic and metabolic effects. It aims to treat advanced liver conditions by reducing fibrosis and ameliorating metabolic dysregulation, a dual approach that positions 89Bio uniquely in the biotech landscape. Beyond its lead candidate, the company continues to explore additional therapeutic avenues within the liver and cardiometabolic realms, ensuring a diversified approach to clinical development.

Clinical Development and Research

89Bio has structured its clinical research around rigorous Phase 3 trials, notably the ENLIGHTEN program, which encompasses pivotal studies in both non-cirrhotic MASH (with fibrosis stages F2-F3) and MASH with compensated cirrhosis (F4). These randomized, double-blind, placebo-controlled trials are designed to evaluate key endpoints such as histological improvements in liver fibrosis and resolution of steatohepatitis. By integrating noninvasive diagnostic tools alongside traditional biopsy assessments, the company aims to streamline patient evaluation and enhance the sensitivity of therapeutic response measurement. Moreover, the advanced design of these trials reflects 89Bio's commitment to scientific excellence and clear regulatory communication, as evidenced by recent supportive designations from global regulatory bodies.

News

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
89bio, Inc. (ETNB) to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference, showcasing their focus on innovative therapies for liver and cardiometabolic diseases. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
-
News

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
89bio, Inc. announced the approval of non-qualified stock options for two new employees as part of the 2023 Inducement Plan. The options allow the purchase of 28,400 shares of the company's common stock at the closing price on the grant date. The options will vest over a four-year period, subject to the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.04%
Tags
none
-
News

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
89bio, Inc. (ETNB) Announces Approval of Non-Qualified Stock Options for New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
News

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary
89bio, Inc. (ETNB) successfully closed an upsized underwritten public offering, raising approximately $172.5 million. The company sold 17,567,567 shares of its common stock and pre-funded warrants to purchase up to 1,081,081 shares. The offering was led by BofA Securities and Leerink Partners, with H.C. Wainwright & Co. as the lead manager. The gross proceeds will be used for the development and commercialization of innovative therapies for liver and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
offering
-
News

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary
89bio, Inc. (ETNB) announces the pricing of an upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25, with expected gross proceeds of approximately $150.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
offering
-
News

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary
89bio, Inc. (ETNB) has announced a public offering of $125.0 million of its common stock or pre-funded warrants. The company aims to use the proceeds for clinical activities, development of pegozafermin, manufacturing scale-up, and general corporate purposes. The offering is subject to market conditions and will be managed by BofA Securities, Leerink Partners, Cantor, Raymond James, UBS Investment Bank, and H.C. Wainwright & Co.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
offering
News

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

Rhea-AI Summary
89bio, Inc. (ETNB) successfully concluded an end-of-Phase 2 Meeting with the FDA, supporting the advancement of pegozafermin into Phase 3 in NASH. The program will include two Phase 3 trials evaluating patients with NASH: ENLIGHTEN-Cirrhosis for F4 patients and ENLIGHTEN-Fibrosis for F2-F3 patients. The FDA has agreed to an accelerated approval pathway for both F4 and F2-F3 NASH patients using histology. The safety database will include data from the ongoing SHTG Phase 3 program. The trials will include patients on background GLP-1 therapy to assess the potential combination with pegozafermin. The ENLIGHTEN program will evaluate the efficacy and safety of pegozafermin in patients with NASH, with the trials expected to initiate in the first and second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.74%
Tags
clinical trial
-
News

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

Rhea-AI Summary
89bio, a clinical-stage biopharmaceutical company (ETNB) focused on liver and cardiometabolic disease therapies, announced positive Phase 2b ENLIVEN trial data for pegozafermin in NASH patients. The 48-week treatment demonstrated sustained improvements in liver health markers, including liver fat, inflammation, and fibrosis, with favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
clinical trial
-
News

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

Rhea-AI Summary
89bio, Inc. (ETNB) to participate in fireside chat at Evercore HEALTHCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences
News

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

Rhea-AI Summary
89bio, Inc. (Nasdaq: ETNB) announces new data from ENLIVEN Phase 2b trial on pegozafermin treatment for F4 NASH patients. Results show improvements in liver specific biomarkers, fibrosis, and inflammation, with a responder analysis suggesting a correlation between NIT-based improvements and histological measures. Safety profile remains favorable. The company plans to initiate Phase 3 program in the first half of next year pending regulatory feedback.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of 89Bio (ETNB)?

The current stock price of 89Bio (ETNB) is $6.06 as of April 18, 2025.

What is the market cap of 89Bio (ETNB)?

The market cap of 89Bio (ETNB) is approximately 807.3M.

What is 89Bio, Inc. known for?

89Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for liver and cardiometabolic diseases. Its scientific expertise is demonstrated through advanced therapeutic candidates such as pegozafermin, a glycoPEGylated analog of FGF21.

What therapeutic areas does 89Bio target?

The company targets liver diseases, specifically metabolic dysfunction-associated steatohepatitis (MASH), and cardiometabolic conditions such as severe hypertriglyceridemia. These areas represent significant unmet clinical needs, fueling 89Bio's strategic research and development efforts.

What is pegozafermin and why is it important?

Pegozafermin is 89Bio's lead product candidate, designed as a glycoPEGylated analog of FGF21. It is engineered to improve liver fibrosis and regulate metabolic parameters, offering a novel dual mechanism that is critical for treating complex conditions like MASH and SHTG.

How is 89Bio advancing its clinical programs?

89Bio is advancing its clinical programs through a series of rigorously designed Phase 3 trials, including the ENLIGHTEN program for MASH. These trials use robust methodologies, combining noninvasive diagnostic techniques with traditional histological assessments to evaluate therapeutic efficacy.

What differentiates the glycoPEGylated technology used by 89Bio?

The glycoPEGylated technology enhances the stability and prolongs the half-life of therapeutic molecules, such as pegozafermin. This technology optimizes biological activity, ensuring sustained efficacy while potentially improving safety and patient adherence through more convenient dosing schedules.

Where is 89Bio headquartered and what is its background?

89Bio is headquartered in San Francisco, California, and was founded in 2018. Since its inception, the company has been dedicated to addressing critical unmet needs in liver and cardiometabolic diseases through advanced therapeutic research and clinical innovation.
Stock ETNB logo
89Bio, Inc.

Nasdaq:ETNB

ETNB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ETNB Stock Data

807.29M
143.21M
1%
93.98%
6.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO